Aukera Therapeutics is a preclinical stage company developing the first RAPTOR inhibitors, a new approach to selectively modulate the proven target mTORC1. The lead program focuses on genetically-driven epilepsies such as TSC. Future use include age-related and neurodegenerative diseases.
- http://www.aukera-tx.com
- +41 61 207 60 81
- Send an email
- Stefan Imseng
